20B Stock Overview
An oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Biomark Diagnostics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.13 |
| 52 Week High | €0.22 |
| 52 Week Low | €0.12 |
| Beta | -0.46 |
| 11 Month Change | -10.07% |
| 3 Month Change | 3.31% |
| 1 Year Change | -24.70% |
| 33 Year Change | -24.70% |
| 5 Year Change | -40.48% |
| Change since IPO | -80.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 20B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -15.0% | 0.8% | -0.4% |
| 1Y | -24.7% | -16.7% | 7.1% |
Return vs Industry: 20B underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 20B underperformed the German Market which returned 7.8% over the past year.
Price Volatility
| 20B volatility | |
|---|---|
| 20B Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 20B's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 20B's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Rashid Ahmed Bux | www.biomarkdiagnostics.com |
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts.
Biomark Diagnostics Inc. Fundamentals Summary
| 20B fundamental statistics | |
|---|---|
| Market cap | €12.18m |
| Earnings (TTM) | -€1.11m |
| Revenue (TTM) | €109.79k |
103.5x
P/S Ratio-10.3x
P/E RatioIs 20B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 20B income statement (TTM) | |
|---|---|
| Revenue | CA$161.79k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$161.79k |
| Other Expenses | CA$1.79m |
| Earnings | -CA$1.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,008.61% |
| Debt/Equity Ratio | -119.6% |
How did 20B perform over the long term?
See historical performance and comparison